Defining the prognosis of early stage chronic lymphocytic leukaemia patients

Incidence of therapy-related myeloid neoplasia after initial therapy for chronic lymphocytic leukemia with fludarabine-cyclophosphamide versus fludarabine: long-term follow-up of US Intergroup Study E2997

(2011) M. R. Smith et al.   BLOOD

Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial

(2010) M Hallek et al.   LANCET

Therapy-related myelodysplastic syndrome and acute myeloid leukemia following fludarabine combination chemotherapy

(2010) D A Carney et al.   LEUKEMIA

Detailed analysis of p53 pathway defects in fludarabine-refractory chronic lymphocytic leukemia (CLL): dissecting the contribution of 17p deletion, TP53 mutation, p53-p21 dysfunction, and miR34a in a prospective clinical trial

(2009) T. Zenz et al.   BLOOD

De novo deletion 17p13.1 chronic lymphocytic leukemia shows significant clinical heterogeneity: the M. D. Anderson and Mayo Clinic experience

(2009) C. S. Tam et al.   BLOOD

Beta2-microglobulin is a better predictor of treatment-free survival in patients with chronic lymphocytic leukaemia if adjusted according to glomerular filtration rate

(2009) Julio Delgado et al.   BRITISH JOURNAL OF HAEMATOLOGY

Predictive value of  2-microglobulin ( 2-m) levels in chronic lymphocytic leukemia since Binet A stages

(2009) M. Gentile et al.   HAEMATOLOGICA

The utility of a prognostic index for predicting time to first treatment in early chronic lymphocytic leukemia: the GIMEMA experience

(2009) S. Molica et al.   HAEMATOLOGICA

Relative value of ZAP-70, CD38, and immunoglobulin mutation status in predicting aggressive disease in chronic lymphocytic leukemia

(2008) L. Z. Rassenti et al.   BLOOD

Monoallelic TP53 inactivation is associated with poor prognosis in chronic lymphocytic leukemia: results from a detailed genetic characterization with long-term follow-up

(2008) T. Zenz et al.   BLOOD

Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines

(2008) M. Hallek et al.   BLOOD

Validation of a new prognostic index for patients with chronic lymphocytic leukemia

(2008) Tait D. Shanafelt et al.   CANCER

A subset of Binet stage A CLL patients with TP53 abnormalities and mutated IGHV genes have stable disease

(2008) O G Best et al.   LEUKEMIA

Expression of ZAP-70 in patients with chronic lymphocytic leukemia may change significantly during the course of the disease

(2007) L. Smolej et al.   International Journal of Laboratory Hematology